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ABSTRACT
Background: Proenkephalin (pro-ENK) was recently found to be associated with low estimated glom-
erular filtration rate (eGFR). The association of pro-ENK with urinary albumin excretion (UAE), another
marker for chronic kidney disease (CKD), has not been investigated. We examined the association of
pro-ENK with eGFR and UAE as markers of CKD.
Methods: We included 4375 subjects of the Prevention of Renal and Vascular End-Stage Disease
(PREVEND) study. CKDeGFR was defined as development of eGFR<60ml/min/1.73 m
2 and CKDUAE as
albuminuria>30mg/24h.
Results: Baseline median pro-ENK was 52.2 (IQR: 44.9–60.5) pmol/L. After a median follow-up of 8.4
(IQR: 7.9–8.9) years, 183 subjects developed CKDeGFR and 371 developed CKDUAE. The association of
pro-ENK with CKDeGFR was modified by sex (Pinteraction< 0.1), in such a way that after adjustment, the
association only remained significant in men (adjusted hazard ratio per SD increase in 10log-trans-
formed pro-ENK, 1.65; 95% CI: 1.15–2.36) and not in women (0.83; 0.58–1.20). No significant association
was observed between pro-ENK and CKDUAE risk (0.83; 0.58–1.20).
Conclusions: High pro-ENK is associated with increased risk of CKDeGFR in men, but not in women. No
association of pro-ENK with CKDUAE was observed. These results should be interpreted with caution,
since residual confounding and potential overfitting of models could have influenced the results.
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Chronic kidney disease (CKD) is a major public health prob-
lem, with adverse outcomes of kidney failure, cardiovascular
disease and premature death (Levey et al. 2009). Early identi-
fication of CKD is needed to prevent disease progression,
reduce the risk of cardiovascular morbidity and mortality,
and improve survival and quality of life.
Recently, pro-enkephalin (pro-ENK) was introduced as a
potential new biomarker for identifying normal subjects at
high risk of future decline in renal function. Pro-ENK is a sta-
ble precursor fragment of unstable enkephalins, which are
well-known endogenous opioid peptides, and it has been
hypothesized that enkephalins play an important biological
function in renal physiology because of dense expression of
enkephalin-responsive delta-opioid receptors in the kidney
(Denning et al. 2008). It has been shown that stimulation of
delta-opioid receptors with selective agonists results in a pro-
found diuretic and natriuretic response in conscious rats
(Sezen et al. 1998), which likely results in a reduction of
energy consumption and workload of the kidneys (Kiil 1977).
Enkephalins have also been implicated in decreasing energy
consumption and protection of the heart (van den Brink
et al. 2003). Together, an increase in pro-ENK may be a com-
pensatory response to either an initial decline of function of
the heart, decline of renal function, or both, protecting organ
function from further decline in both the acute and chronic
situation (Kieneker et al. 2017, Ng et al. 2017).
In previous clinical studies, cross-sectional associations
were observed for elevated levels of pro-ENK with severity of
acute kidney injury (Smith et al. 1981, Zoccali et al. 1987), or
chronic renal failure (Marino et al. 2015, Shah et al. 2015), but
also a prospective association was found between high pro-
ENK and increased risk of graft failure among renal transplant
recipients (Kieneker et al. 2017). Moreover, recently Schulz
et al. (2017) observed that high concentrations of circulating
pro-ENK were associated with renal function decline during
follow-up in 2568 participants of the Malm€o Diet and Cancer
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study. Interestingly, genome-wide association analysis in 4150
participants of the same cohort revealed genetic variation at
the PENK locus that was associated with higher pro-ENK
levels and with higher incidence in CKD, suggesting a causal
relationship between pro-ENK and CKD defined as an esti-
mated glomerular filtration rate (eGFR)< 60ml/min/1.73m2.
However, it is unclear whether pro-ENK is also associated with
increased risk of developing increased albuminuria, the other
main variable that defines CKD (Levey et al. 2011, 2015), which
Schulz and colleagues could not take into account. In stable
renal transplant recipients, a higher pro-ENK was cross-section-
ally associated with urinary albumin excretion (UAE) (Kieneker
et al. 2017), however, no prospective data are yet available.
Therefore, the aim of the present study was to replicate
the association of pro-ENK with low eGFR as a marker of
CKD, and to investigate whether pro-ENK is associated with
risk of developing high UAE.
Clinical significance
 Early identification of CKD is needed to prevent disease
progression, reduce the risk of cardiovascular morbidity
and mortality, and improve survival and quality of life.
 In the present study, high concentrations of plasma pro-
ENK are associated with an increased risk of developing
CKDeGFR in men, but not in women.
 Further investigations are needed to determine whether
pro-ENK might aid in early identification of subjects at
high risk of future CKDeGFR.
Methods
Study design and population
The Prevention of Renal and Vascular End-stage Disease
(PREVEND) study is a prospective investigation of albumin-
uria, renal and cardiovascular disease in a large cohort drawn
from the general population. The details of this study are
described elsewhere (Hillege et al. 2001). In brief, from 1997
to 1998, all inhabitants of Groningen, the Netherlands aged
28–75 years, were sent a questionnaire and a vial to collect a
first morning void urine sample. Pregnant women and sub-
jects with type 1 diabetes mellitus were excluded. Urinary
albumin concentration (UAC) was assessed in 40,856 res-
ponders. Subjects with a UAC of 10mg/L (n¼ 7768) were
invited to participate, of whom 6000 were enrolled. In add-
ition, a randomly selected group with a UAC of <10mg/L
(n¼ 3394) was invited to participate in the cohort, of whom
2592 were enrolled. These 8592 individuals form the
PREVEND cohort and completed an extensive examination in
1997 and 1998 (baseline). The second screening took place
from 2001 through 2003 (N¼ 6894), which was the starting
point of the present evaluation. Of these 6894, we excluded
Figure 1. Flow diagram of the participants in the study.
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subjects with missing values of pro-ENK (n¼ 157), subjects
with CKD at baseline or unknown CKD status (n¼ 1727), or
with no follow-up data available for CKD (n¼ 635), leaving
4375 participants for the analyses. The flow diagram of the
participants is displayed in Figure 1.
The PREVEND study has been approved by the medical
ethics committee of the University Medical Center Groningen
and is performed in accordance with Declaration of
Helsinki guidelines. Written informed consent was obtained
from all participants.
Data collection
The procedures at each examination in the PREVEND study
have been described in detail previously (Halbesma et al.
2008). In brief, each examination included two visits to an
outpatient clinic separated by 3 weeks. Prior to the first visit,
all participants completed a self-administered questionnaire
regarding demographics, cardiovascular and renal disease
history, smoking habits, alcohol consumption and medication
use. Information on medication use was combined with infor-
mation from community pharmacies. During the first visit,
participants’ height and weight were assessed. During each
examination and during each visit, blood pressure was meas-
ured on the right arm, every minute for 10 and 8min,
respectively, by an automatic Dinamap XL Model 9300 series
device (Johnson-Johnson Medical, Tampa, FL). The mean of
the last two recordings from each of the two visits was used.
In the last week before the second visit, subjects had to col-
lect two consecutive 24-h specimens after thorough oral and
written instruction. The collected urine was stored cold (4 C)
for a maximum of 4 days before the second visit. After hand-
ing in the urine collections, the urine specimens were stored
at 20 C. Furthermore, fasting blood samples were provided
and stored at 80 C.
Laboratory procedures
Urine electrolytes were directly analyzed according to stand-
ard laboratory procedures. Concentrations of total cholesterol,
high-density lipoprotein (HDL) cholesterol, triglycerides and
glucose were determined as previously described (Verhave
et al. 2004, Oterdoom et al. 2009). Measurement of serum cre-
atinine was performed by an isotope dilution mass spectrom-
etry (IDMS) traceable enzymatic method on a Roche Modular
analyzer using reagents and calibrators from Roche (Roche
Diagnostics, Mannheim, Germany), with intra- and interassay
coefficients of variation of 0.9% and 2.9%, respectively. Serum
cystatin C concentrations were measured by Gentian Cystatin
C Immunoassay (Gentian AS, Moss, Norway) on a Modular ana-
lyzer (Roche Diagnostics). Cystatin C was calibrated directly
using the standard supplied by the manufacturer (traceable to
the International Federation of Clinical Chemistry Working
Group for Standardization of Serum Cystatin C) (Grubb et al.
2010). The intra- and interassay coefficients of variation were-
<4.1% and<3.3%, respectively. UAC was measured by neph-
elometry with a threshold of 2.3mg/L, and intra- and
interassay coefficients of variation of 2.2% and 2.6%, respect-
ively (Dade Behring Diagnostic, Marburg, Germany).
Measurement of proenkephalin (pro-ENK)
An assay for stable pro-ENK (amino acids 119–159 of pro-ENK
A) has been previously reported (Ernst et al. 2006) and was
modified as recently described (Ng et al. 2014). In brief, two
mouse monoclonal anti-pro-ENK antibodies were developed
by immunization with pro-ENK peptide (amino acids 119–159
of pro-ENK A). One antibody (2 mg) was used to coat polystyr-
ene tubes. The other antibody labelled with methyl-acridi-
nium ester served as the detector antibody. Standards (pro-
ENK peptide; amino acids 119–159 of pro-ENK A) and sam-
ples (50 ml) were incubated in tubes with the detector anti-
body (150 ml). After equilibration, tubes were washed and
bound chemiluminescence was detected with a luminometer
LB952T/16 (Berthold, Bad Wildbad, Germany). The lower
detection limit of the assay was 5.5 pmol/L. Intra- and interas-
say coefficients of variation were, 6.4% and 9.5% at 50 pmol/
L, and 4.0% and 6.5% at 150 pmol/L, respectively. The assay
was provided by Sphingotec GmbH (Hennigsdorf, Germany).
Ascertainment of outcomes
Development of CKD was defined as reaching an
eGFR<60ml/min per 1.73 m2 (CKDeGFR) or an UAE>30mg
per 24 h (CKDUAE) de novo (Koning et al. 2015). We estimated
GFR with the combined creatinine cystatin C-based Chronic
Kidney Disease Epidemiology (CKD-EPI) Collaboration equa-
tion from 2012, taking into account age, sex and race (Inker
et al. 2012). UAC was multiplied by urine volume to obtain
UAE expressed as mg per 24 h. The two 24-h UAE values of
each subject per examination were averaged.
Assessment of covariates
Smoking status was defined as self-reported never smoker,
former smoker or current smoker (<6, 6–20 or >20 ciga-
rettes/day). Parental history of CKD was defined as having a
first-degree relative who had a renal disease requiring dialysis
for>6 weeks. Educational level was defined as low (primary
education or intermediate vocational education), middle
(higher secondary education) and high (higher vocational
education and university).
Statistical analyses
Baseline characteristics are presented according to sex-spe-
cific quintiles of pro-ENK. Continuous data are presented as
mean with SD or as median and interquartile range (IQR) in
case of skewed distribution. Categorical data are presented
as percentiles. Univariable and multivariable linear regression
were performed to determine whether patients’ characteris-
tics were associated with pro-ENK concentrations. The
Pearson’s product–moment correlation coefficient was calcu-
lated for the associations of pro-ENK with UAE and eGFR.
To study the prospective association of pro-ENK with risk
of developing CKDeGFR and CKDUAE while taking to account
the oversampling of subjects with albuminuria, design-based
Cox proportional hazards regression analysis was used to
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calculate hazard ratios (HRs) and 95% confidence intervals
(CIs). Pro-ENK was analyzed as a continuous term per SD
10log-transformed increment of pro-ENK and in quintiles.
Nonlinearity was tested by using the likelihood ratio test,
comparing nested models with linear or linear and cubic
spline terms. We first calculated HRs (95% CIs) for the crude
model. Second, age- and sex-adjusted HRs (95% CIs) were
calculated (multivariable model 1). Additionally, we calculated
HRs (95% CIs) which were further adjusted for body mass
index (BMI), alcohol consumption, smoking status, and sys-
tolic blood pressure, HDL, triglycerides, glucose, and urinary
urea, creatinine, and albumin excretion (multivariable model
2); and eGFR (multivariable model 3). We evaluated potential
effect modification by sex, age, BMI, and baseline eGFR and
UAE in the analyses of risk of CKD by fitting models contain-
ing both main effects and their cross-product terms.
In case we observed an association, we evaluated whether
pro-ENK adds additional prognostic information for risk pre-
diction on top of baseline eGFR and a multivariable model
including baseline eGFR, by testing differences in the
Harrell’s C-statistics and the 2 log likelihood of prediction
models with and without inclusion of pro-ENK in the model.
We performed sensitivity analyses to examine the robust-
ness of the associations between pro-ENK and risk of CKD, by
defining CKDeGFR as an eGFR<66ml/min/1.73 m
2 (instead of
<60ml/min per 1.73 m2) and CKDUAE as an UAE>25mg/24 h
(instead of >30mg/24 h) for a more pronounced decline in kid-
ney function in order to reach the primary outcome of CKD.
All p values are two-tailed. A p value<0.05 was consid-
ered statistically significant. All analyses were conducted with
the use of the statistical package IBM SPSS (version 22; SPSS




Baseline median pro-ENK was 52.2 pmol/L (IQR:
44.9–60.5 pmol/L), with higher values in women (54.4; IQR:
47.0–63.0 pmol/L) than in men (50.2; IQR: 43.2–57.7 pmol/L;
p< 0.001). Baseline characteristics are shown according to
quintiles of pro-ENK (Table 1). Compared to subjects with
low pro-ENK at baseline, subjects with high pro-ENK concen-
trations were more likely to be female, older, to consume
less alcohol, to have a lower BMI, lower systolic and diastolic
blood pressure, and to have slightly higher HDL cholesterol
and lower triglycerides concentrations. Additionally, these
same individuals were more likely to have a lower plasma
glucose, a lower eGFR, and a lower urinary excretion of albu-
min, creatinine and urea.
Cross-sectional associations
Baseline pro-ENK was inversely correlated with eGFR
(r¼0.27, p< 0.001; Figure 2) and UAE (r¼0.09, p< 0.001).
Table 2 shows the associations between log-transformed pro-
ENK levels and variables of interest due to their association
with pro-ENK or because of their involvement in the develop-
ment of CKD. In crude analyses, female sex, age, and HDL
cholesterol were positively associated with pro-ENK, whereas
use of alcohol, BMI, systolic blood pressure, triglycerides, glu-
cose, eGFR and urinary excretions of albumin, creatinine and
urea were inversely associated with pro-ENK.
When adding all the variables in a multivariable model,
significant independent positive associations with pro-ENK
were observed for HDL cholesterol, and use of antihyperten-
sive and glucose-lowering drugs, whereas inverse
Table 1. Baseline characteristics of the 4375 participants of the PREVEND study according to quintiles of pro-enkephalin.
Quintiles of pro-ENK, pmol/L
<43.3 43.3–49.3 49.4–55.3 55.4–62.9 >62.9
p value
for trenda
Participants, N 875 875 875 875 875
Women, % 38.7 47.8 51.1 57.9 65.7 <0.001
Age, years 51.1 ± 9.9 51.6 ± 10.9 51.7 ± 11.0 51.2 ± 11.5 52.5 ± 11.9 0.03
Race, whites, % 96.6 96.1 96.0 96.9 94.7 0.13
Parental history of CKD, % 0.9 1.6 1.8 1.3 2.6 0.02
Smoking status, never, % 31.5 28.8 31.2 32.5 32.6 0.82
Alcohol consumption, none, % 20.7 22.1 22.7 23.8 27.1 <0.001
Education, high, % 31.7 35.2 35.2 34.5 31.3 0.13
BMI, kg/m2 27.5 ± 4.3 26.7 ± 4.1 26.3 ± 4.0 25.6 ± 4.0 25.3 ± 3.8 <0.001
Systolic blood pressure, mm Hg 125 ± 16 124 ± 16 123 ± 16 121 ± 17 122 ± 18 <0.001
Diastolic blood pressure, mm Hg 74 ± 8 73 ± 9 72 ± 9 71 ± 8 72 ± 9 <0.001
Antihypertensive drugs, % 16.3 16.1 13.6 14.8 19.0 0.35
Total cholesterol, mmol/L 5.4 ± 1.0 5.5 ± 1.0 5.4 ± 1.0 5.4 ± 1.1 5.4 ± 1.0 0.20
HDL cholesterol, mmol/L 1.2 ± 0.3 1.3 ± 0.3 1.3 ± 0.3 1.3 ± 0.3 1.3 ± 0.3 <0.001
LDL cholesterol, mmol/L 3.6 ± 0.9 3.6 ± 0.9 3.6 ± 0.9 3.5 ± 1.0 3.5 ± 0.9 0.13
Triglycerides, mmol/L 1.17 (0.82–1.69) 1.13 (0.80–1.55) 1.03 (0.77–1.49) 1.05 (0.77–1.44) 1.02 (0.74–1.47) <0.001
Lipid-lowering drugs, % 6.2 5.9 7.1 9.0 6.7 0.14
Glucose, mmol/L 5.1 ± 1.2 5.0 ± 0.9 4.8 ± 0.9 4.8 ± 0.9 4.8 ± 0.8 <0.001
Glucose-lowering drugs, % 2.3 0.9 1.0 1.7 0.6 0.13
eGFR, ml/min/1.73 m2 100 ± 13 97 ± 14 95 ± 14 95 ± 14 89 ± 15 <0.001
Urinary albumin excretion, mmol/24 h 8.2 (6.3–11.8) 8.3 (5.9–11.8) 7.6 (5.7–11.0) 7.3 (5.7–10.6) 7.1 (5.4–10.2) <0.001
Urinary creatinine excretion, mg/24 h 13.6 (11.3–16.0) 12.5 (10.4–15.0) 11.9 (10.2–14.8) 11.5 (9.7–13.8) 10.7 (9.0–13.1) <0.001
Urinary urea excretion, mmol/24 h 391 (319–474) 368 (290–438) 360 (294–436) 345 (284–412) 324 (263–392) <0.001
Continuous variables are reported as mean ± SD or median (interquartile range) and categorical variables are reported as percentage.
aDetermined by linear-by-linear association chi-square test (categorical variables) and linear regression (continuous variables).
BMI: body mass index; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; PREVEND: Prevention of Renal and Vascular End-stage Disease.
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independent associations were observed for age, BMI, trigly-
cerides, glucose, eGFR, and urinary creatinine and urea excre-
tion. When excluding either baseline eGFR or urinary
creatinine excretion, female sex was significantly associated
with higher levels of pro-ENK (standardized b¼ 0.048,
p¼ 0.03 and standardized b¼ 0.021, p< 0.01, respectively).
The multivariable model had an adjusted R2 of 0.204, with
eGFR being the most important contributing determinant
(partial R2¼ 0.093), suggesting that a large percentage of cir-
culating pro-ENK levels may be explained by eGFR.
Association of pro-ENK with risk of developing CKD
During a median follow-up of 8.4 years (IQR: 7.9–8.9 years),
183 cases of CKDeGFR and 371 cases of CKDUAE occurred. The
association of pro-ENK with CKDeGFR risk was modified by sex
(Pinteraction<0.1). The Kaplan–Meier curves for CKDeGFR and
CKDUAE survival according to quintiles of pro-ENK and strati-
fied for sex are presented in Figure 3. In the crude model
stratified for sex, high pro-ENK was associated with increased
risk of CKDeGFR in men (HR: 2.66; 95% CI: 2.13–3.32; Table 3)
and in women, although less strong (HR: 1.64; 95% CI:
1.25–2.15). The associations remained similar after adjustment
for age, BMI, alcohol consumption, smoking status, systolic
blood pressure, HDL cholesterol, triglycerides, glucose, and
urinary urea, creatinine, and albumin excretion (HR for men:
2.71; 95% CI: 1.96–3.77 and HR for women: 1.58; 95% CI:
1.16–2.16). However, after further adjustment for baseline
eGFR, associations were strongly attenuated in both men and
women, resulting in a weakened, but significant association
in men (HR: 1.65; 95% CI: 1.15–2.36) and a non-significant
association in women (HR: 0.83; 95% CI: 0.58–1.20). When
adjusting for baseline eGFR alone, the association of pro-ENK
with CKDeGFR risk remained in men (HR: 1.42; 95% CI:
Figure 2. Association of pro-ENK with baseline eGFR (A) and UAE (B) in 4375 participants of the PREVEND study. eGFR: estimated glomerular filtration rate; UAE:
urinary albumin excretion; PREVEND: Prevention of Renal and Vascular End-stage Disease; pro-ENK: proenkephalin.
Table 2. Uni- and multivariable linear regression analyses with log-transformed pro-enkephalin as dependent variable
in 4375 participants of the PREVEND study.
Univariable Multivariable (R2¼ 0.204)
Variables R2 Standardized b p value Partial R2 Standardized b p value
Sex, female vs. male 0.036 0.191 <0.001 0 0.008 0.69
Age, years 0.001 0.041 0.007 0.018 0.201 <0.001
Caucasian, yes vs. no <0.001 0.023 0.13 0 0.007 0.61
Parental history of CKD, yes vs. no <0.001 0.004 0.81 0 0.003 0.85
Smoking, yes vs. no 0.001 0.038 0.11 0 0.007 0.63
Alcohol, yes vs. no 0.003 0.057 <0.001 0 0.022 0.13
Education high, yes vs. no <0.001 0.013 0.39 0 0.018 0.24
BMI, kg/m2 0.037 0.193 <0.001 0.019 0.169 <0.001
Systolic blood pressure, mm Hg 0.006 0.079 <0.001 0 0.002 0.91
Antihypertensive drugs, yes vs. no <0.001 0.023 0.16 0.001 0.032 0.04
HDL cholesterol, mmol/L 0.022 0.148 <0.001 0.001 0.036 0.04
LDL cholesterol, mmol/L <0.001 0.019 0.18 0 0.008 0.60
Triglycerides, mmol/L 0.009 0.098 <0.001 0.001 0.032 0.04
Lipid-lowering drugs, yes vs. no <0.001 0.018 0.25 0 0.015 0.34
Glucose, mmol/L 0.012 0.111 <0.001 0.003 0.056 <0.001
Glucose-lowering drugs, yes vs. no <0.001 0.024 0.11 0.005 0.072 <0.001
eGFR, ml/min/1.73 m2 0.072 0.269 <0.001 0.093 0.400 <0.001
Urinary albumin excretion, mmol/24 h 0.007 0.085 <0.001 0 0.004 0.80
Urinary creatinine excretion, mmol/24 h 0.075 0.275 <0.001 0.015 0.181 <0.001
Urinary urea excretion, mmol/24 h 0.040 0.200 <0.001 0.001 0.035 0.04
BMI: body mass index; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; HDL: high-density lipo-
protein; LDL: low-density lipoprotein; PREVEND: Prevention of Rena land Vascular End-stage Disease; pro-ENK:
proenkephalin.
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1.06–1.89), but not in women (HR: 0.81; 95% CI: 0.61–1.08).
We did not find evidence for effect-modification by age and
BMI in the association of pro-ENK with risk of CKDeGFR (all
Pinteraction>0.1).
No associations were observed for pro-ENK with risk of
CKDUAE in the crude (HR: 0.90; 95% CI: 0.76–1.06; Table 3) or
multivariable adjusted model (HR: 0.95; 95% CI: 0.77–1.17).
Also no evidence for effect-modification by sex, age and BMI
was observed (all Pinteraction> 0.1). We did not analyze the
combined endpoint of CKD defined as eGFR<60ml/min/1.73
m2 and/or UAE>30mg/24 h, because of the different associa-
tions (linear vs. tendency to U-shape).
Results remained essentially similar when we excluded sub-
jects at baseline with an eGFR<66ml/min/1.73 m2 (instead of
<60ml/min/1.73 m2) (N¼ 4282, n¼ 120; HR for men: 1.65; 95%
CI: 1.21–2.26 and HR for women: 0.89; 95% CI: 0.67–1.18) and a
UAE>25mg/24 h (instead of >30mg/24 h) (N¼ 4256, n¼ 293;
Q1: HR: 1.71; 95% CI: 1.19–2.46; Q5:1.37; 95% CI: 0.93–2.01) for
a more pronounced decline in kidney function during follow-
up before reaching the CKD endpoints.
Additional prognostic value of pro-ENK
When analyzing the additional prognostic value of pro-ENK
on top of baseline eGFR for the prediction of CKDeGFR in men
by comparing Harrell’s C-statistics of prediction models with
and without pro-ENK, no significant difference was observed
(p for comparison¼ 0.15; Supplementary Table S1). However,
when investigating differences in the 2 log likelihood of
the model including baseline eGFR with and without inclu-
sion of pro-ENK, the 2 log likelihood significantly improved
with pro-ENK included in the model (p for comparison <0.01;
Supplementary Table S1).
Figure 3. Kaplan–Meier curves for CKDeGFR and CKDUAE survival according to quintiles of pro-ENK. Upper panels represent the Kaplan–Meier survival curves for
CKDeGFR for men (A) and women (B), whereas the lower panels represent the Kaplan–Meier survival curves for CKDUAE for men (C) and women (D). CKDeGFR: chronic
kidney disease defined as estimated glomerular filtration rate<60ml/min/1.72 m2; CKDUAE: chronic kidney disease defined as urinary albumin excretion>30mg/
24 h; pro-ENK: proenkephalin.
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When analyzing the additional prognostic value of pro-
ENK on top of the multivariable model including baseline
eGFR for the prediction of CKDeGFR in men, we observed sig-
nificant improvement of both the Harrell’s C-statistics as well
as the 2 log likelihood when pro-ENK was included in the
model (p¼ 0.02 and p< 0.01, respectively; Supplementary
Table S1).
Discussion
In this prospective population-based cohort study free of
CKD at baseline, a higher concentration of pro-ENK was asso-
ciated with an increased risk of developing CKDeGFR in men,
but not in women. No association of pro-ENK with risk of
developing CKDUAE was observed.
Despite comparable baseline eGFR and pro-ENK levels in
this study compared to the study of Schulz et al. (2017), we
could only replicate their finding of a decreased eGFR during
follow-up with a higher pro-ENK in men, but not in women.
In total, they studied 2568 participants without CKD at base-
line of the population-based Malm€o Diet and Cancer Study
Cardiovascular cohort during a mean follow-up of 16.6 years.
An increased risk of CKDeGFR was observed for subjects with
a higher baseline pro-ENK. A possible explanation for the dif-
ference in observed associations could be the difference in
baseline age range between the cohorts, since the age most
of the study participants of the Malm€o Diet and Cancer
Study Cardiovascular cohort study ranged between
50–60 years (mean age 56.4 ± 5.7 years) versus 33–75 years
(mean age 51.6 ± 11.1 years) in the PREVEND study. Therefore,
the incidence rate of CKDeGFR was about 30% in contrast to
our incidence rate of 4%. An interaction of age was observed
in their study, however, in such a way that high pro-ENK was
associated with decline in eGFR in the youngest individuals.
No interactions with age were observed in the present study.
When comparing prediction models for CKDeGFR risk in
men by means of Harrell’s C-statistics for models including
baseline eGFR with and without pro-ENK, no significant dif-
ference was observed between both models. However, since
the Harrell’s C-statistics is based on ranks rather than on con-
tinuous data, it is very insensitive to detect differences
(Harrell 2001, Cook 2007). To avoid injudicious discarding of
otherwise promising biomarkers, it is therefore currently rec-
ommended to also compare prediction models by means of
more sensitive methods, like the 2 log likelihood method
(Harrell 2001, Cook 2007). When using the 2 log likelihood
method, we observed a significantly improvement for
CKDeGFR risk in men of the model including pro-ENK. When
comparing the additional prognostic value of pro-ENK on top
of the multivariable adjusted model including baseline eGFR
for the prediction of CKDeGFR in men, significant improve-
ments of both the Harrell’s C-statistics as well as the 2 log
likelihood were observed when pro-ENK was included in the
model. This indicates that the model including pro-ENK had
a modest, but significant, higher predictive capacity for
CKDeGFR risk in men on top of other risk factors including
baseline eGFR.
This study is the first to examine the association of pro-
ENK with risk of CKD defined as UAE>30mg/24 h.
Albuminuria is an important component in the diagnosis and
Table 3. Association between pro-ENK and risk of developing chronic kidney disease (CKDeGFR and CKDUAE) in 4375 participants of the PREVEND study
a.
Log pro-ENK
Quintiles of pro-ENK, pmol/L
Per SD increment <43.3 43.3–49.3 49.4–55.3 55.4–62.9 >62.9
CKDeGFR – men
Person-years 12,981 3410 2916 2675 2253 1727
Cases 84 4 9 17 17 37
Crude model 2.66 (2.13–3.32) 0.10 (0.03–0.33) 0.61 (0.18–2.03) 1.00 (ref) 1.51 (0.56–4.09) 4.96 (2.15–11.45)
Age-adjusted model 2.38 (1.81–3.11) 0.13(0.04–0.46) 0.73 (0.22–2.49) 1.00 (ref) 1.28 (0.45–3.58) 4.55 (1.97–10.49)
Multivariable model 1b 2.57 (1.87–3.54) 0.13 (0.04–0.48) 0.63 (0.18–2.27) 1.00 (ref) 1.25 (0.45–3.50) 3.95 (1.64–9.54)
Multivariable model 2c 2.71 (1.96–3.77) 0.09 (0.02–0.34) 0.51 (0.13–1.94) 1.00 (ref) 1.28 (0.43–3.84) 3.79 (1.70–8.44)
Multivariable model 3d 1.65 (1.15–2.36) 0.17 (0.04–0.76) 0.86 (0.22–3.38) 1.00 (ref) 1.50 (0.42–5.33) 2.00 (0.83–4.78)
CKDeGFR – women
Person-years 13,947 2134 2610 2745 3068 3390
Cases 99 6 13 13 28 39
Crude model 1.64 (1.25–2.15) 0.67 (0.19–2.31) 0.99 (0.35–2.77) 1.00 (ref) 1.96 (0.81–4.72) 2.42 (1.05–5.58)
Age-adjusted model 1.44 (1.09–1.90) 1.06 (0.30–3.79) 1.13 (0.40–3.22) 1.00 (ref) 2.09 (0.86–5.07) 2.45 (1.05–5.68)
Multivariable model 1b 1.56 (1.17–2.09) 0.89 (0.23–3.42) 1.11 (0.39–3.17) 1.00 (ref) 2.04 (0.82–5.09) 2.67 (1.08–6.60)
Multivariable model 2c 1.58 (1.16–2.16) 0.61 (0.13–3.02) 1.23 (0.42–3.59) 1.00 (ref) 2.04 (0.79–5.22) 2.53 (0.95–6.76)
Multivariable model 3d 0.83 (0.58–1.20) 1.78 (0.43–7.42) 2.56 (0.86–7.61) 1.00 (ref) 1.94 (0.80–4.72) 1.13 (0.44–2.88)
CKDUAE
Person-years 28,707 5704 5749 5808 5853 5593
Cases 372 95 76 67 62 72
Crude model 0.90 (0.76–1.06) 1.37 (0.86–2.16) 1.08 (0.67–1.76) 1.00 (ref) 0.81 (0.49–1.36) 0.98 (0.60–1.60)
Age- and sex-adjusted model 0.90 (0.76–1.08) 1.44 (0.91–2.29) 1.13 (0.70–1.84) 1.00 (ref) 0.87 (0.52–1.46) 1.04 (0.63–1.70)
Multivariable model 1b 0.89 (0.74–1.06) 1.47 (0.92–2.35) 1.12 (0.69–1.82) 1.00 (ref) 0.84 (0.50–1.41) 1.01 (0.62–1.64)
Multivariable model 2c 0.93 (0.76–1.13) 1.54 (0.93–2.53) 0.90 (0.55–1.49) 1.00 (ref) 0.96 (0.56–1.65) 1.10 (0.66–1.82)
Multivariable model 3d 0.95 (0.77–1.17) 1.18 (0.72–1.93) 0.82 (0.72–1.93) 1.00 (ref) 0.98 (0.58–1.66) 1.35 (0.79–2.28)
CKDeGFR is defined as eGFR<60ml/min/1.73 m
2 and CKDUAE is defined as urinary albumin excretion>30mg/24 h.
aHRs (95% CIs) were derived from design-based Cox proportional hazard models.
bMultivariable model 1 is additionally adjusted for BMI, alcohol consumption, smoking status and systolic blood pressure.
cMultivariable model 2 is additionally adjusted for HDL cholesterol, triglycerides, glucose, and urinary urea, creatinine, and albumin excretion.
dMultivariable model 3 is additionally adjusted for eGFR.
BMI: body mass index; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; HDL: high-density lipoprotein; PREVEND: Prevention of Renal and
Vascular End-stage Disease; pro-ENK: proenkephalin; UAE: urinary albumin excretion.
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classification of CKD, because albuminuria is an early pre-
dictor of progressive renal function loss and also may indi-
cate a worse renal prognosis (de Jong and Curhan 2006). In
the study of Schulz et al. (2017), no data on UAE were avail-
able, so they could not take UAE into account when exclud-
ing subjects with CKD at baseline and investigate the
prospective association of pro-ENK with risk of developing
CKD based on albuminuria. We did not observe a significant
association of pro-ENK with risk of CKDUAE in the present
study.
Due to the low molecular weight of pro-ENK (4586.60 g/
mol), it is assumed to be freely filtered through the glomeru-
lus and therefore the proposed association of enkephalins
with renal disease therefore likely implies impaired clearance
or increased production of enkephalins in renal disease.
Genome-wide association analysis revealed genetic variation
at the PENK locus that was associated with higher pro-ENK
levels and with higher incidence in CKD, suggesting a causal
relationship between pro-ENK and CKDeGFR (Schulz et al.
2017). Besides inflammation, various other physiological func-
tions have been shown to be modulated by enkephalins,
including processes of cell growth, differentiation, and apop-
tosis (Ovadia et al. 1996, McTavish et al. 2007, Denning et al.
2008, Awad et al. 2012). In an experimental study in con-
scious Sprague-Dawley rats, activation of the delta opioid sys-
tem by infusion of a delta opioid receptor agonist evoked a
profound diuretic and natriuretic response, which suggest
significant changes in renal excretory function (Sezen et al.
1998). We could therefore speculate that an increment in
pro-ENK concentrations could be a reflection of counteract-
ing the decreasing functionality of the kidney by promoting
kidney function. Further experimental studies blocking or
stimulating the opioid receptors could demonstrate the
potential role of pro-ENK in this relationship.
Some limitations of the present study should be noted.
First, the association of pro-ENK with risk of CKDeGFR was
strongly attenuated by adjustment for baseline eGFR.
Arguably, the association observed in men could also be the
result of residual confounding with respect to pro-ENK as a
marker for renal function in addition to eGFR as an estima-
tion of true renal function. Second, because sex was an effect
modifier in the association of pro-ENK with risk of CKDeGFR,
we had to stratify the analyses and therefore the number of
cases could have become insufficient to either detect an
association in women, or overfitting of the model could be
an issue. Third, pro-ENK was only assessed at baseline, and
therefore we could not take into account changes over time
in pro-ENK concentrations. However, when the intra-individ-
ual variability of variables is taken into account, this results in
general in strengthening of associations (Koenig et al. 2003,
Danesh et al. 2004). Therefore, our use of a single pro-ENK
measurement at baseline rather than multiple ones, will likely
provide an underestimation of the true effect, whereas we
now already found an association. Second, eGFR as measure
of kidney function might be a less precise measure for renal
function compared to measured GFR, which was not avail-
able in the PREVEND study, but which is also not feasible in
large scale epidemiological studies with serial follow-up.
Finally, we could not use the combined endpoint of CKD
defined as eGFR<60ml/min/1.73 m2 and/or UAE>30mg/
24 h, because of the different associations (linear vs. tendency
to U-shape).
A strength of this study includes the measurement of
UAE, so that we could assess the association of pro-ENK with
risk of CKDUAE. Another strength of this study is the use of
estimated GFR with the combined creatinine cystatin C-based
CKD-EPI Collaboration equation from 2012, which includes
serum creatinine and cystatin C (Inker et al. 2012). Other
strengths of this study are the prospective design and the
relatively large sample size.
Conclusions
In this prospective cohort study, high concentrations of
plasma pro-ENK are associated with an increased risk of
developing CKDeGFR in men, but not in women. These results
should be interpreted with caution, since residual confound-
ing and potential overfitting of models could have influenced
the results. Further investigations are needed to determine
the association of pro-ENK with risk of CKDeGFR and to deter-
mine whether pro-ENK might aid in early identification of
subjects at high risk of future CKD.
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